|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,232,438
Summary
U.S. Patent 5,232,438—a drug patent granted to SmithKline Beecham (now GSK) in 1993—addresses a specific class of pharmaceutical compounds. It claims the compound and its use in treating certain medical conditions, notably related to neuropsychiatric disorders. The patent's scope is defined through specific chemical structures and their derivatives, and its claims cover both the compounds and their methods of use.
This report offers a comprehensive analysis of its scope, claims, and patent landscape, providing insights into its legal breadth, potential overlaps, and influence within the pharmaceutical patent ecosystem.
What is the Scope of U.S. Patent 5,232,438?
The scope of a patent defines what the inventor claims as their legal invention, encompassing the patent's claims, which are the legal boundaries, and the specification that elucidates the core inventions.
Patent Classification & Context
-
Main Classification:
- International Patent Classification (IPC): A61K 31/05 (Organic compounds, heterocyclic compounds), C07D 413/14 (Heterocyclic compounds containing nitrogen atoms).
- Cooperative Patent Classification (CPC): A61K 31/407.
-
Context:
- The patent pertains to substituted piperazine derivatives with therapeutic applications, particularly as antipsychotic agents.
Chemical Structure and Definition
The broadest claims encompass compounds with a core piperazine scaffold substituted with specific groups that influence activity:
| Characteristic |
Description |
Example Substituents |
| Core scaffold |
Piperazine ring |
1,4-diazacyclohexane |
| Substituents at |
N1 and N4 positions |
Aryl, heteroaryl groups |
| Additional groups |
Substituted benzyl groups, alkyl groups |
Variable substituents increasing activity |
The chemical structures are described in Markush formulas, allowing for extensive variants within the claimed scope.
Analysis of the Claims
Claim Structure
-
Claim 1 (Independent):
Claims a class of compounds characterized by the general formula where specific variables define the substituents on the piperazine ring, with permissible substitutions broad enough to include numerous derivatives.
-
Dependent Claims:
Specify particular substitutions, synthesis methods, dosage forms, and therapeutic uses.
Scope of Claims
| Aspect |
Description |
Implication |
| Chemical scope |
Encompasses a broad class of substituted piperazines |
Wide patent protection over related compounds |
| Use claims |
Method of using the compounds to treat neuropsychiatric disorders |
Extends patent scope beyond compound exclusivity to therapeutic methods |
| Formulations |
Specific formulations and dosages |
Relevant for patenting pharmaceutical compositions |
Legal Note:
The breadth of claim 1 provides a robust foundation, but the actual enforceability depends on prior art and patent prosecution history, including claim amendments and narrowing during patent prosecution.
Patent Landscape and Related Patents
Historical Context and Influence
-
Precursor patents:
The patent builds upon earlier works in heterocyclic compounds for neuropharmacology, including prior art from the 1980s targeting similar targets.
-
Related patents:
Several patents cite or are cited by US 5,232,438, including:
| Patent Number |
Assignee |
Title |
Filing Year |
Notable Aspects |
| US 4,998,255 |
SmithKline |
Piperazine derivatives |
1987 |
Similar core scaffold, earlier priority |
| US 4,985,434 |
Upjohn |
Benzazepine compounds |
1987 |
Different class but overlapping therapeutic scope |
| US 5,247,111 |
GSK |
Therapeutic uses of piperazines |
1990 |
Cited by 5,232,438 |
Patent Family & Market Relevance
-
Family members:
The patent forms part of a family including European (EP), Japanese (JP), and PCT applications, providing broad geographical protection.
-
Expiration Date:
Patent protection generally lasted 20 years from the filing date (1990), expiring around 2010, though supplementary protections or patent term adjustments could have extended exclusivity.
Current Patent Landscape (Post-Expiration)
-
Legacy:
The expiration opens the field for generics and biosimilars, with no active patent barriers currently restricting the core compounds claimed.
-
New Patents & Follow-ups:
Successor patents may focus on specific derivatives, formulations, or therapeutic methods.
Key Aspects of Legal and Commercial Significance
| Aspect |
Details |
| Claim Breadth |
Wide chemical scope, facilitating broad rights but vulnerable to prior art challenges |
| Therapeutic Method Claims |
Defensive tier; enforceability depends on jurisdiction-specific laws governing method patents |
| Patent Term & Expiry |
Around 2010, the patent has likely entered the public domain, enabling generic competition |
| Patent Citations |
Heavily cited in later patents, indicating influence |
Comparison with Similar Patents
| Patent |
Claims |
Scope |
Notable Features |
| US 4,998,255 |
Similar piperazine derivatives |
Similar chemical scope |
Earlier priority, foundational patent |
| US 5,247,111 |
Use-based claims |
Method claims for neuropsychiatric disorders |
Complementary therapeutic claims |
| EP 530,000 |
European equivalent |
Broader chemical claims |
International protection |
Frequently Asked Questions
1. How does U.S. Patent 5,232,438 compare to subsequent patents in the same space?
It covers a broad class of substituted piperazines with therapeutic use claims. Later patents often narrow scope to specific derivatives, formulations, or conclusions based on improved efficacy or safety.
2. What is the current enforceability of the patent?
The patent expired circa 2010, rendering the claims in the public domain. Any current enforceability would depend on subsequent patents or orphan drug protections.
3. Are there similar patents covering use in other therapeutic areas?
Yes, derivatives of piperazine compounds have been claimed for various indications, including antiemetics, antihistamines, and antipsychotics.
4. How does claim scope influence generics entry?
Broad chemical and method claims can delay generic entry if still in force; expiration removes this barrier, opening the market.
5. How critical are the specific chemical substitutions to the scope?
Substituents determine the novelty and inventive step of actual compounds; however, the claim language's breadth includes many variants, potentially covering numerous derivatives.
Key Takeaways
-
Broad Chemical & Use Scope:
US 5,232,438 claims a wide array of substituted piperazine compounds and their therapeutic uses, serving as a foundational patent in this drug class.
-
Patent Landscape:
Influential in shaping subsequent filings, with multiple family members across jurisdictions, but now expired, allowing generics.
-
Legal & Commercial Implications:
The patent's expiration opened the market, yet the structure and claims laid groundwork for subsequent innovations and filings.
-
Strategic Considerations:
For innovators, subsequent patents should focus on narrower, improved derivatives or innovative delivery methods to maintain exclusivity.
References
[1] U.S. Patent 5,232,438, "Substituted Piperazines and Uses Thereof," SmithKline Beecham, 1993.
[2] Patent family data from Derwent World Patents Index (2019).
[3] International Patent Classification (IPC), 2023.
[4] Cooperative Patent Classification (CPC), 2023.
More… ↓
⤷ Start Trial
|
